You are here: Industry Insights > glioblastoma

News List

AIVITA Biomedical Completes Treatment of Patients in Glioblastoma Immunotherapy Trial americanpharmaceuticalreview
November 11, 2020
AIVITA Biomedical announced treatment has been completed for all 57 patients in the Phase 2 clinical trial of AV-GBM-1 in patients with glioblastoma.
Trodelvy from Immunomedics gets US FDA orphan drug designation for glioblastoma expresspharma
October 14, 2020
Trodelvy has shown encouraging activity in an early-stage study in brain cancers, including partial responses in small cohorts of patients with brain metastasis from breast cancer and recurrent glioblastoma, informed the company.
MimiVax SurVaxM, Pembrolizumab Study Opens for Recurrent Glioblastoma Patients americanpharmaceuticalreview
June 10, 2020
MimiVax announced a clinical collaboration to assess the combination of SurVaxM and pembrolizumab.
MediciNova Receives Notice of Allowance for Second Patent Covering Glioblastoma Treatment americanpharmaceuticalreview
April 24, 2020
MediciNova has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of glioblastoma.
Researchers identify immune-suppressing target in glioblastoma worldpharmanews
December 24, 2019
Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with ...
Zotiraciclib granted Orphan Drug Designation by FDA and EMA europeanpharmaceuticalreview
December 09, 2019
The FDA and EMA have granted Orphan Drug Designation to zotiraciclib, currently the subject of two separate Phase Ib clinical trials in glioblastoma.
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference En-CPhI.CN
November 26, 2019
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in ...
Bristol-Myers Squibb Announces Opdivo Glioblastoma Study Does Not Meet PFS Primary Endpoint americanpharmaceuticalreview
September 06, 2019
Bristol-Myers Squibb announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus the standard ...
Ziopharm Oncology Achieves Positive Results for Glioblastoma Treatment contractpharma
June 19, 2019
Controlled IL-12 platform appears to have activity as a monotherapy and is now being studied in an expanded group of patients.
Cleveland researchers test novel gene therapy for glioblastoma worldpharmanews
June 10, 2019
Cleveland researchers test novel gene therapy for glioblastoma.

Previous page 1 2 3 4 Next page